Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)

January 23, 2024 11:13 AM EST

Novo Nordisk continues to stack obesity pipeline, this time with Swiss zebrafish biotech

Lei Lei Wu

News Reporter

Novo Nordisk licensed an experimental obesity pill from EraCal Therapeutics in a deal worth €235 million, or roughly $255 million, as it hunts for the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo Nordisk continues to stack obesity pipeline, this time with Swiss zebrafish biotech

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

No­vo Nordisk con­tin­ues to stack obe­si­ty pipeline, this time with Swiss ze­brafish biotech

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novo Nordisk continues to stack obesity pipeline, this time with Swiss zebrafish biotech